In all, 49 cases of ACBCP were reported between 1966 and 2006; clinical and diagnostic information was available for 43. The mean (range) age of the 43 patients was 64 (28-87) years, and follow-up was available for 30 (70%) of these, with a mean of 38 (3-144) months. All follow-up details were limited to the time of publication of the case report. The presenting symptoms and signs of the cases are showed in Table 1 . Obstructive LUTS were the most common (37, 89%) presenting complaint. A few investigators reported the DRE findings as a large, benign prostate, which was characteristically 'elastic' [12] [13] [14] ; 29 (68%) of the BCCs were diagnosed by TURP and seven (16%) and six (14%) were diagnosed by prostatic needle biopsy and open prostatectomy, respectively. ACC was an incidental finding in one patient who had a retropubic radical prostatectomy (RRP) for classic adenocarcinoma [3] .
The pathological characteristics are also given in Table 1 ; ACC (67%) was twice common as BC (23%). Synchronous classic adenocarcinoma of prostate was found in nine patients (19%) . No imaging methods were recorded as being effective in diagnosing BCC, although one report described the presence of numerous tiny cysts on TRUS [15] . Table 1 also shows the definitive treatment in 43 cases; a third of patients had RRP and TURP as definitive treatment, respectively. Five patients had tumour involving the bladder and/or rectum and had pelvic exenteration. No patient had metastasis at presentation. Two patients were not treated [3, 16] .
Among the 30 patients with follow-up data, 19 (63%) were reported to be free of recurrence; five (17%) were alive with tumour and five (17%) had diseasespecific death. One (3%) patient died from unrelated causes; Table 2 shows the outcome related to pathological diagnosis and definitive treatment. Of seven (23%) patients developing distant metastases, six were ACC and one was a BC. Four (13%) patients with ACC and one (3%) with a mixedpattern tumour developed local recurrence. None of those with BC developed local recurrence. One patient with metastasis and associated TCC of the bladder was not included in the outcome analysis [17] .
DISCUSSION
The human prostatic epithelium is composed of three major cell types, secretory epithelial, neuroendocrine and basal; the secretory epithelial cells are the most common. These are tall columnar cells with secretory granules and enzymes that stain for acid phosphatase and PSA. The neuroendocrine cells, also termed amine precursor uptake decarboxylase cells, are present in significant numbers in normal prostate gland. The basal cells are small and round with little cytoplasm and large irregular nuclei. They are described as undifferentiated keratin rich (types 4, 5 and 6) pluripotent cells [18] . They are less common (10%) and have no secretory function. It is postulated that basal cells could be the stem cells of the prostate [19] . These cells can be identified by immunohistochemical staining
INTRODUCTION
Prostate cancer is the leading solid cancer and the second most common cause of cancerrelated death in men in the USA; the current annual incidence is estimated to be 234 000 [1] . Classical adenocarcinoma is the most common histological variant in prostate cancer. Small-cell, colloid, mesenchymal and metastatic tumours are other histological variants. Basal cell carcinoma (BCC) of the prostate is a rare variant, comprising < 0.01% of malignant tumours of the prostate [2] .
Lesions arising from the basal cells of the prostate span a histologically heterogeneous spectrum. On one end there is classic basal cell hyperplasia (BCH), a benign lesion; at the other end there is evidence that there are two distinct yet related malignant lesions. They have been termed adenoid cystic carcinoma (ACC) and basaloid carcinoma (BC). These can occur separately or as mixed tumours with one pattern predominating [3] .
In 1974, Frankel and Craig [4] first described ACC in the prostate, which was characterized by extensive infiltration of nests of basaloid cells between normal prostate glands. There is no consensus on the nomenclature of these tumours and several, often confusing, terms have been used interchangeably. These include BCC [3, 5] , ACC [3, 6] , adenoid cysticlike tumour [7] , adenoid basal cell tumour [8, 9] and basaloid tumour [6, 10] . Randolph et al. [11] grouped the lesions under the common heading of AC/BC of the prostate (ACBCP). It was suggested that these tumours have an indolent biological potential with a good prognosis, and require less aggressive treatment than acinar adenocarcinoma [3, 7, 10, 11] . However, due the lack of follow-up their biological
with specific anti-cytokeratin monoclonal antibodies (34 β E12) [20] . It is essential to study the biology of basal cells to understand the behaviour of tumours originating from them.
Basal cell proliferations of the prostate have been described using various terms [3, [6] [7] [8] [9] [10] , ranging from benign BCH to malignant AC/ basaloid tumours. At one limit is classic BCH, a benign lesion, which is characterized by the presence of glands containing multiple layers of basal cells with benign cytological features [21] . It is a lesion of elderly men that occurs in the transition zone of the prostate and is frequently associated with benign adenomatous hyperplasia [6] ; they are typically multifocal and frequently show squamous differentiation. Montironi et al. [22] and Yang et al. [23] described the presence of intracytoplasmic globules as a characteristic feature of BCH. The criteria for diagnosing BCH are well established (Table 3 ) [6] . As this lesion occurs in the transition zone it is more often diagnosed by TURP than by needle biopsies from the peripheral zone [24, 25] . Variants of BCH have been described; atypical BCH is identical to the classic form at low magnification but is characterized by nuclear enlargement and prominent nucleoli at higher magnification. Another benign basal cell proliferation, basal cell adenoma, has been described in association with nodular hyperplasia of the prostate [8] .
The malignant tumours from basal cells are the AC and basaloid variants. The pathological description of classical ACC is characterized by cylinders of hyalinized or mucinous stroma surrounded by nests of small epithelial cells, which give the tissue a perforated, sieve-like or cribriform appearance. These tumours occur in the salivary glands, mammary glands, mucous glands of the upper and lower respiratory tract, and rarely in the prostate. They are malignant but slow-growing, and tend to spread locally via the nerves.
ACC of the prostate occurs in younger patients and frequently arises or infiltrates the peripheral zone. McKenney et al. [6] showed that the mean age of patients with ACC and BCH was 46 and 72 years, respectively. Prominent cribriform morphology, extensive glandular interanastomosis and pseudocysts containing basophilic secretion are classical features [3, 6] . This closely resembles the ACC of salivary glands [26] , which originate from 
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myoepithelial cells or intercalated ducts [27] , but as yet there is no evidence of myoepithelial components in human prostate gland.
However, the basaloid pattern, or BC, is similar to BCC of the skin. The prostate is infiltrated by irregular solid clumps, trabeculae and larger cellular masses composed of basaloid cells. The cells have uniform small, round or oval nuclei with scant cytoplasm [10, 28] . While there is peripheral pallisading, cribriforming is absent or minimal [6, 10, 28] . There are no consistent criteria to differentiate benign from malignant basal cell tumours. Rare morphological patterns of BCH with cellular atypia make diagnostic terminology more difficult [8, 21] .
The WHO classification of tumours of the urinary system and male genital organs proposed that the malignant basal cell tumours, including AC and basaloid variants, be classified under a single term 'BCC' [29] . It also issued specific criteria to distinguish benign and malignant basal cell proliferations; these include an infiltrative pattern, extraprostatic extension, perineural invasion, necrosis and stromal desmoplasia [29] . A review of pathological criteria for diagnosing BCC of the prostate in previous published case reports did not adhere to the above guidelines. The key feature that was used to differentiate these tumours from benign BCH and its variants was the presence of basaloid cells in irregular, variably sized nests which infiltrate between normal prostate glands [3, 4, 7, 8] . Lack of follow-up and absence of documentation of clinically aggressive behaviour of these cases make the diagnosis questionable in some of the reported cases [2, 4, 5, 10, [30] [31] [32] [33] .
Iczkowski et al. [3] reviewed and reported 19 cases of basal cell neoplasm of the prostate. The criteria of diagnosis was primarily the infiltrative pattern of a desmoplastic stroma. Six patients were diagnosed to have predominantly adenoid and six were basaloid patterns. Only two patients had perineural invasion; six of them had extraprostatic extension. Tumour necrosis was present in two cases. Four patients had metastatic disease, of which three were adenoid cystic and one was basaloid that had metastasized to the lungs and corpora cavernosa.
McKenney et al. [6] presented an excellent review of 23 cases, consisting of 19 benign, three ACC and one BC. They identified young age, involvement of peripheral zone of the prostate, extraprostatic spread, perineural and periglandular invasion as the important criteria in differentiating benign and malignant tumours. They also noted that BC was predominantly in the transition zone, with minimal or absent hyalinization and no cribriforming. The invasion was mainly perineural and periglandular, while in ACC it was perineural and extraprostatic. Table 3 shows the histopathological differentiation of benign and malignant tumours.
Immunohistochemistry studies were available for 22 cases [3, 6, 25, 26, 28] . The enzyme markers (PSA and prostatic acid phosphatase, PAP), cytokeratin markers (high molecular weight anti-keratin, HMW-CK 34 β E12, cytokeratin 7, 14 and 20) and myoepithelial markers (smooth muscle actin, calponin, smooth muscle myosin heavy chain, S-100 protein, vimentin) are frequently assessed in suspected basal cell proliferations. PSA and PAP stain the secretory epithelial cells and are useful to identify the PSA-producing acinar adenocarcinoma of prostate. Basal cellspecific HMW-CK 34 β E12 stains virtually all normal basal cells of the prostate [3, 6, 9, 34] . Benign basal cell lesions are also positive for 34 β E12. Secretory and stromal cells are not stained. McKenney et al. showed that four of five BPH and all three ACC showed cytoplasmic immunoreactivity for HMW-CK 34 β E12 [6] . Most of the reports on BCC were negative for enzyme markers like PSA and PAP, which are hallmarks of classical adenocarcinoma [3, 6, 9, 25, 28] . This feature is used to differentiate the BCC from poorly differentiated adenocarcinoma, which can mimic BCC and is not reactive to PSA. Lack of immunoreactivity to HMW-CK helps to exclude basal cell proliferation and in turn helps in the diagnosis of adenocarcinoma of prostate. P63 is another marker that stains for basal cells and rarely secretory cells when they are poorly differentiated. Shah et al. [35] studied the diagnostic usefulness of HMW-CK and P63 together as a cocktail, which was better for identifying basal cell lesions than was HMW-CK and P63 alone. No myoepithelial marker was strongly positive for BCC [6, 28, 34] . Interestingly, one case of BC reported by McKenney et al. [6] showed no reactivity with any immune marker. It is difficult to reach any conclusion with the report from one case of BC in their series. Markers such as the expression of CD44, P53, C-erbB-2 and Ki-67 proliferation index were assessed, with variable results [23, 28, 36] . To date, immunohistochemistry is not precise in differentiating the benign and malignant basal cell proliferations, but it is useful in differentiating BCC from prostatic adenocarcinoma.
There is no consensus on the management of BCC; some initial reports suggested that BCC has an excellent prognosis with a benign biological behaviour [4, 31] . It is difficult to define the optimum management when the diagnostic criteria were not uniform in all reports. McKenney et al. [6] suggested that many of the reported BCCs have been diagnosed with no definitive histological evidence of malignancy or aggressive clinical course.
Overall, a third of patients (14/43) were treated with TURP and a third with RRP (13/ 43); seven and eight who had RRP and TURP, respectively, were alive and had no recurrence at the time of reporting. One patient with ACC who had TURP subsequently recurred and had RRP, with a documented disease-free period of 36 months [15] . One man who had RRP recurred after 7 years and received external beam radiotherapy [13] , and another presented with distant metastases in lung, liver and corpus cavernosum [3] . However, there was no disease-specific death in either the TURP or RRP groups. It is arguable that the patients who had TURP might not have had histological features strongly supporting malignancy, hence they were treated conservatively. Five patients had pelvic exenteration and three had chemo-and radiation therapy for locally advanced disease. Three of the five patients who had pelvic exenteration and two of three who had chemo-radiation had disease-specific death at a mean of 38 (5.5-108) months. One patient who refused any intervention returned with abdominal metastases at 28 months [16] . Five patients had local recurrence and seven had distant metastasis [3, 6, 16] ; four of those with local recurrences and six of those with metastases were diagnosed as having ACC. One patient with BC developed metastases and one with a mixed pattern developed local recurrence. All five patients who had a disease-specific death had ACC.
The review of management and outcome suggests that previously patients labelled as having BCC could represent the whole spectrum of basal cell proliferations. However, it is understood that BCC has two distinct histological variants, both of which have the potential to invade locally, mainly along the nerves, and to metastasize distally. Of these, ACC is more aggressive than BC. This evidence suggests that radical surgery is the preferred first-line management option. A lifelong follow-up is necessary, as local recurrence and metastasis can develop. Immunohistochemical techniques can be used to differentiate this tumour from other undifferentiated prostate and bladder tumours.
CONCLUSION
BCH or ACH typically occur in elderly men in the transition zone of the prostate, invariably in association with BPH [6, 25] . BCC is a rare tumour with clinical and pathological features distinct from classic adenocarcinoma of prostate. Although the 2004 WHO classification clarifies many aspects of basal cell neoplasm, it classifies malignant basal cell tumours under a combined diagnostic term, BCC [29] . However, in view of distinct morphological and immunohistochemical properties among AC and basaloid variants, we prefer to keep these variants well distinguished in the classification, as suggested by McKenney et al. [6] . Although the biological behaviour is not fully understood, it is now clear that these tumours have the potential to invade locally and metastasize distally in time. Current evidence suggests that radical surgery is the preferred first-line management option. A life-long follow-up is necessary, as local recurrence and metastasis can develop.
